Which companies overlap with Oriental Neurosurgery Evidence-Based-Study Team's portfolio?

Top competitors by shared drug class: Samsung Medical Center, University of Kansas Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/oriental-neurosurgery-evidence-based-study-team.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Oriental Neurosurgery Evidence-Based-Study Team — Portfolio Competitive Intelligence Brief

Oriental Neurosurgery Evidence-Based-Study Team pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Samsung Medical Center · 1 shared drug class
University of Kansas Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Oriental Neurosurgery Evidence-Based-Study Team:

Cite this brief

Drug Landscape (2026). Oriental Neurosurgery Evidence-Based-Study Team — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oriental-neurosurgery-evidence-based-study-team. Accessed 2026-05-16.